2264-2265 / 2437
172 patients
171 patients
343 patients
randomise
crizotinib
cisplat/carbo
pemetrexed
PROFILE trial 1014
ALK+ advanced NSCLC
Brain metastases in patients with ALK-positive NSCLC
Solomon
et al 2016, J Clin Oncol; 34 (24), 2858-65